Balyasny Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Balyasny Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-51,816	Closed	-$389K	–	3422
2022 Q2	$389K	Buy	+51,816	New	+$365K	﹤0.01%	2051
2021 Q4	–	Sell	-262,835	Closed	-$3M	–	2725
2021 Q3	$3M	Buy	+262,835	New	+$3.84M	0.01%	991
2020 Q2	–	Sell	-197,844	Closed	-$2.67M	–	1593
2020 Q1	$2.67M	Buy	+197,844	New	+$3.75M	0.03%	556
2019 Q4	–	Sell	-255,164	Closed	-$4.9M	–	1576
2019 Q3	$4.9M	Buy	+255,164	New	+$5.85M	0.03%	553
2019 Q1	–	Sell	-35,611	Closed	-$1.29M	–	1742
2018 Q4	$1.29M	Sell	35,611 -286,572	-89%	-$13.4M	0.01%	828
2018 Q3	$19.8M	Sell	322,183 -63,059	-16%	-$4.05M	0.09%	306
2018 Q2	$26M	Buy	385,242 +328,442	+578%	+$18.4M	0.12%	242
2018 Q1	$3.08M	Sell	56,800 -25,189	-31%	-$1.41M	0.01%	865
2017 Q4	$4.9M	Buy	+81,989	New	+$4.97M	0.02%	869
2015 Q4	–	Sell	-200,000	Closed	-$3.55M	–	1511
2015 Q3	$3.55M	Buy	+200,000	New	+$3.62M	0.03%	575

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's AERI Position: Q3 2022 in Review

Balyasny Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 51,816 shares — an estimated $389K sold.

Balyasny Asset Management first reported a position in AERI in Q3 2015 and held it in 10 quarters. The position peaked at $26M in Q2 2018. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

Balyasny Asset Management reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Balyasny Asset Management sold 51,816 Aerie Pharmaceuticals shares in Q3 2022, an estimated $389K.
Balyasny Asset Management first reported a position in Aerie Pharmaceuticals in Q3 2015 and held it in 10 quarters.
Balyasny Asset Management's Aerie Pharmaceuticals position peaked at $26M in Q2 2018.
156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Balyasny Asset Management's 13F filing for Q3 2022, filed 15 Nov 2022.